<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31195981</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-3658</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular medicine (Cambridge, Mass.)</Title>
          <ISOAbbreviation>Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.</ArticleTitle>
        <Pagination>
          <StartPage>26</StartPage>
          <MedlinePgn>26</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">26</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s10020-019-0085-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Non-alcoholic fatty liver disease (NAFLD) is a common hepatic disease with an increasing prevalence but an unclear aetiology. This study aimed to investigate the functional implications of microRNA-122 (miR-122) in the pathogenesis of NAFLD and the possible molecular mechanisms.</AbstractText>
          <AbstractText Label="METHODS">Both in vitro and in vivo models of NAFLD were generated by treating HepG2 and Huh-7 cells with free fatty acids (FFA) and by feeding mice a high-fat diet (HFD), respectively. HE and Oil Red O staining were used to examine liver tissue morphology and lipid deposition, respectively. Immunohistochemical (IHC) staining was used to examine Sirt1 expression in liver tissues. qRT-PCR and Western blotting were employed to measure the expression of miR-122, Sirt1, and proteins involved in lipogenesis and the AMPK pathway. Enzyme-linked immunosorbent assay (ELISA) was used to quantify triglyceride (TG) levels in HepG2 and Huh-7 cells and in liver tissues. The interaction between miR-122 and the Sirt1 gene was further examined by a dual luciferase reporter assay and RNA-immunoprecipitation (RIP).</AbstractText>
          <AbstractText Label="RESULTS">NAFLD hepatic tissues and FFA-treated HepG2 and Huh-7 cells presented excess lipid production and TG secretion, accompanied by miR-122 upregulation, Sirt1 downregulation, and potentiated lipogenesis-related genes. miR-122 suppressed Sirt1 expression via binding to its 3'-untranslated region (UTR). Knockdown of miR-122 effectively mitigated excessive lipid production and suppressed the expression of lipogenic genes in FFA-treated HepG2 and Huh-7 cells via upregulating Sirt1. Furthermore, miR-122 knockdown activated the LKB1/AMPK signalling pathway.</AbstractText>
          <AbstractText Label="CONCLUSION">The inhibition of miR-122 protects hepatocytes from lipid metabolic disorders such as NAFLD and suppresses lipogenesis via elevating Sirt1 and activating the AMPK pathway. These data support miR-122 as a promising biomarker and drug target for NAFLD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Long</LastName>
            <ForeName>Jun-Ke</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No.139, Middle Renmin Road, Changsha, 410011, Hunan Province, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No.139, Middle Renmin Road, Changsha, 410011, Hunan Province, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Ya-Wen</ForeName>
            <Initials>YW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urological Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, 410011, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Shui-Ping</ForeName>
            <Initials>SP</Initials>
            <Identifier Source="ORCID">0000-0002-5561-5868</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No.139, Middle Renmin Road, Changsha, 410011, Hunan Province, People's Republic of China. zhaoshuiping03@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>06</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Med</MedlineTA>
        <NlmUniqueID>9501023</NlmUniqueID>
        <ISSNLinking>1076-1551</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C531907">MIRN122 microRNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.-</RegistryNumber>
          <NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050155" MajorTopicYN="N">Lipogenesis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065626" MajorTopicYN="N">Non-alcoholic Fatty Liver Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056564" MajorTopicYN="N">Sirtuin 1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">AMPK pathway</Keyword>
        <Keyword MajorTopicYN="Y">Lipogenesis</Keyword>
        <Keyword MajorTopicYN="Y">Non-alcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="Y">Sirt1</Keyword>
        <Keyword MajorTopicYN="Y">miR-122</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31195981</ArticleId>
        <ArticleId IdType="pmc">PMC6567918</ArticleId>
        <ArticleId IdType="doi">10.1186/s10020-019-0085-2</ArticleId>
        <ArticleId IdType="pii">10.1186/s10020-019-0085-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol. 2016;16:141. doi: 10.1186/s12876-016-0557-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12876-016-0557-6</ArticleId>
            <ArticleId IdType="pmc">PMC5153912</ArticleId>
            <ArticleId IdType="pubmed">27955628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alizadeh E, Akbarzadeh A, Eslaminejad MB, Barzegar A, Hashemzadeh S, Nejati-Koshki K, Zarghami N. Up regulation of liver-enriched transcription factors HNF4a and HNF6 and liver-specific microRNA (miR-122) by inhibition of let-7b in mesenchymal stem cells. Chem Biol Drug Des. 2015;85:268–279. doi: 10.1111/cbdd.12398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cbdd.12398</ArticleId>
            <ArticleId IdType="pubmed">25059576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ao R, Wang Y, Tong J, Wang BF. Altered microRNA-9 expression level is directly correlated with pathogenesis of nonalcoholic fatty liver disease by targeting Onecut2 and SIRT1. Med Sci Monit. 2016;22:3804–3819. doi: 10.12659/MSM.897207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/MSM.897207</ArticleId>
            <ArticleId IdType="pmc">PMC5074799</ArticleId>
            <ArticleId IdType="pubmed">27756894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandt S, Roos J, Inzaghi E, Kotnik P, Kovac J, Battelino T, Cianfarani S, Nobili V, Colajacomo M, Kratzer W, Denzer C, Fischer-Posovszky P, Wabitsch M. Circulating levels of miR-122 and nonalcoholic fatty liver disease in pre-pubertal obese children. Pediatr Obes. 2018;13:175–182. doi: 10.1111/ijpo.12261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ijpo.12261</ArticleId>
            <ArticleId IdType="pubmed">29271122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braza-Boils A, Mari-Alexandre J, Molina P, Arnau MA, Barcelo-Molina M, Domingo D, Girbes J, Giner J, Martinez-Dolz L, Zorio E. Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease. Liver Int. 2016;36:1221–1229. doi: 10.1111/liv.13097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/liv.13097</ArticleId>
            <ArticleId IdType="pubmed">26901384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056–1060. doi: 10.1038/nature07813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07813</ArticleId>
            <ArticleId IdType="pmc">PMC3616311</ArticleId>
            <ArticleId IdType="pubmed">19262508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013;58:119–125. doi: 10.1016/j.jhep.2012.08.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2012.08.008</ArticleId>
            <ArticleId IdType="pubmed">22902550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ceccarelli S, Panera N, Gnani D, Nobili V. Dual role of microRNAs in NAFLD. Int J Mol Sci. 2013;14:8437–8455. doi: 10.3390/ijms14048437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms14048437</ArticleId>
            <ArticleId IdType="pmc">PMC3645753</ArticleId>
            <ArticleId IdType="pubmed">23594995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Zhao M, Huang J, Li Y, Wang S, Harrington CA, Qian DZ, Sun XX, Dai MS. microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1. J Cell Biochem. 2018;119:4945–4956. doi: 10.1002/jcb.26739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.26739</ArticleId>
            <ArticleId IdType="pubmed">29384218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu MJ, Hickey AJ, Tagaloa S, Zhang L, Dare AJ, MacDonald JR, Yeong ML, Bartlett AS, Phillips AR. Ob/Ob mouse livers show decreased oxidative phosphorylation efficiencies and anaerobic capacities after cold ischemia. PLoS One. 2014;9:e100609. doi: 10.1371/journal.pone.0100609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0100609</ArticleId>
            <ArticleId IdType="pmc">PMC4067359</ArticleId>
            <ArticleId IdType="pubmed">24956382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colak Y, Yesil A, Mutlu HH, Caklili OT, Ulasoglu C, Senates E, Takir M, Kostek O, Yilmaz Y, Enc FY, Tasan G, Tuncer I. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. J Gastrointestin Liver Dis. 2014;23:311–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25267960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>da Silva-Santi LG, Antunes MM, Caparroz-Assef SM, Carbonera F, Masi LN, Curi R, Visentainer JV, Bazotte RB. Liver fatty acid composition and inflammation in mice fed with high-carbohydrate diet or high-fat diet. Nutrients. 2016;8:682. doi: 10.3390/nu8110682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu8110682</ArticleId>
            <ArticleId IdType="pmc">PMC5133070</ArticleId>
            <ArticleId IdType="pubmed">27801862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond) 2017;14:49. doi: 10.1186/s12986-017-0206-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12986-017-0206-2</ArticleId>
            <ArticleId IdType="pmc">PMC5539973</ArticleId>
            <ArticleId IdType="pubmed">28775758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore) 2017;96:e8179. doi: 10.1097/MD.0000000000008179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000008179</ArticleId>
            <ArticleId IdType="pmc">PMC5626318</ArticleId>
            <ArticleId IdType="pubmed">28953675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int. 2007;27:708–715. doi: 10.1111/j.1478-3231.2007.01497.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1478-3231.2007.01497.x</ArticleId>
            <ArticleId IdType="pubmed">17498258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gormand A, Berggreen C, Amar L, Henriksson E, Lund I, Albinsson S, Goransson O. LKB1 signalling attenuates early events of adipogenesis and responds to adipogenic cues. J Mol Endocrinol. 2014;53:117–130. doi: 10.1530/JME-13-0296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/JME-13-0296</ArticleId>
            <ArticleId IdType="pubmed">24859970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, Serrano M. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3. doi: 10.1038/ncomms1001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms1001</ArticleId>
            <ArticleId IdType="pmc">PMC3641391</ArticleId>
            <ArticleId IdType="pubmed">20975665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X, Zhang J, Jiang Y, Lei Y, Lu L, Zhou J, Huang H, Fang D, Tao G. Effect on metabolic enzymes and thyroid receptors induced by BDE-47 by activation the pregnane X receptor in HepG2, a human hepatoma cell line. Toxicol in Vitro. 2014;28:1377–1385. doi: 10.1016/j.tiv.2014.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tiv.2014.07.004</ArticleId>
            <ArticleId IdType="pubmed">25063376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X-Z, Wen D, Zhang M, Xie Q, Ma L, Guan Y, Ren Y, Chen J, Hao C-M. Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-β/Smad3 pathway. J Cell Biochem. 2014;115:996–1005. doi: 10.1002/jcb.24748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.24748</ArticleId>
            <ArticleId IdType="pubmed">24356887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403:795–800. doi: 10.1038/35001622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35001622</ArticleId>
            <ArticleId IdType="pubmed">10693811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S. Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD) Microrna. 2018;7:215–222. doi: 10.2174/2211536607666180531093302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/2211536607666180531093302</ArticleId>
            <ArticleId IdType="pubmed">29848284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia L, Li W, Li J, Li Y, Song H, Luan Y, Qi H, Ma L, Lu X, Yang Y. Lycium barbarum polysaccharide attenuates high-fat diet-induced hepatic steatosis by up-regulating SIRT1 expression and deacetylase activity. Sci Rep. 2016;6:36209. doi: 10.1038/srep36209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep36209</ArticleId>
            <ArticleId IdType="pmc">PMC5099939</ArticleId>
            <ArticleId IdType="pubmed">27824080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HJ, Joe Y, Yu JK, Chen Y, Jeong SO, Mani N, Cho GJ, Pae HO, Ryter SW, Chung HT. Carbon monoxide protects against hepatic ischemia/reperfusion injury by modulating the miR-34a/SIRT1 pathway. Biochim Biophys Acta. 2015;1852:1550–1559. doi: 10.1016/j.bbadis.2015.04.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2015.04.017</ArticleId>
            <ArticleId IdType="pubmed">25916635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem. 2008;283:27628–27635. doi: 10.1074/jbc.M805711200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M805711200</ArticleId>
            <ArticleId IdType="pmc">PMC2562073</ArticleId>
            <ArticleId IdType="pubmed">18687677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latorre J, Moreno-Navarrete JM, Mercader JM, Sabater M, Rovira O, Girones J, Ricart W, Fernandez-Real JM, Ortega FJ. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD. Int J Obes. 2017;41:620–630. doi: 10.1038/ijo.2017.21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ijo.2017.21</ArticleId>
            <ArticleId IdType="pubmed">28119530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X. SIRT1 and energy metabolism. Acta Biochim Biophys Sin Shanghai. 2013;45:51–60. doi: 10.1093/abbs/gms108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/abbs/gms108</ArticleId>
            <ArticleId IdType="pmc">PMC3527007</ArticleId>
            <ArticleId IdType="pubmed">23257294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Lian F, Liu C, Hu KQ, Wang XD. Isocaloric pair-fed high-carbohydrate diet induced more hepatic steatosis and inflammation than high-fat diet mediated by miR-34a/SIRT1 Axis in mice. Sci Rep. 2015;5:16774. doi: 10.1038/srep16774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep16774</ArticleId>
            <ArticleId IdType="pmc">PMC4660435</ArticleId>
            <ArticleId IdType="pubmed">26608583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin MJ, Dai W, Scott MJ, Li R, Zhang YQ, Yang Y, Chen LZ, Huang XS. Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRalpha signaling pathway. Oncotarget. 2017;8:108802–108809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5752482</ArticleId>
            <ArticleId IdType="pubmed">29312569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin R, Elf S, Shan C, Kang HB, Ji Q, Zhou L, Hitosugi T, Zhang L, Zhang S, Seo JH, Xie J, Tucker M, Gu TL, Sudderth J, Jiang L, Mitsche M, DeBerardinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Hurwitz SJ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Lei Q, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 2015;17:1484–1496. doi: 10.1038/ncb3255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3255</ArticleId>
            <ArticleId IdType="pmc">PMC4628560</ArticleId>
            <ArticleId IdType="pubmed">26479318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L, Nakao K. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 2014;34:e302–e307. doi: 10.1111/liv.12429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/liv.12429</ArticleId>
            <ArticleId IdType="pubmed">24313922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nassir F, Ibdah JA. Sirtuins and nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22:10084–10092. doi: 10.3748/wjg.v22.i46.10084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v22.i46.10084</ArticleId>
            <ArticleId IdType="pmc">PMC5155167</ArticleId>
            <ArticleId IdType="pubmed">28028356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng R, Wu H, Xiao H, Chen X, Willenbring H, Steer CJ, Song G. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology. 2014;60:554–564. doi: 10.1002/hep.27153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27153</ArticleId>
            <ArticleId IdType="pmc">PMC4809671</ArticleId>
            <ArticleId IdType="pubmed">24677249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panera N, Gnani D, Crudele A, Ceccarelli S, Nobili V, Alisi A. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15079–15086. doi: 10.3748/wjg.v20.i41.15079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i41.15079</ArticleId>
            <ArticleId IdType="pmc">PMC4223241</ArticleId>
            <ArticleId IdType="pubmed">25386056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800–812. doi: 10.1136/gutjnl-2014-306996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2014-306996</ArticleId>
            <ArticleId IdType="pmc">PMC4277726</ArticleId>
            <ArticleId IdType="pubmed">24973316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9:327–338. doi: 10.1016/j.cmet.2009.02.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2009.02.006</ArticleId>
            <ArticleId IdType="pmc">PMC2668535</ArticleId>
            <ArticleId IdType="pubmed">19356714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13:239–250. doi: 10.1038/nrm3313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3313</ArticleId>
            <ArticleId IdType="pmc">PMC4021399</ArticleId>
            <ArticleId IdType="pubmed">22436747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santamarina AB, Oliveira JL, Silva FP, Carnier J, Mennitti LV, Santana AA, de Souza GH, Ribeiro EB, Oller do Nascimento CM, Lira FS, Oyama LM. Green tea extract rich in Epigallocatechin-3-Gallate prevents fatty liver by AMPK activation via LKB1 in mice fed a high-fat diet. PLoS One. 2015;10:e0141227. doi: 10.1371/journal.pone.0141227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0141227</ArticleId>
            <ArticleId IdType="pmc">PMC4633218</ArticleId>
            <ArticleId IdType="pubmed">26536464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sendi H, Mead I, Wan M, Mehrab-Mohseni M, Koch K, Atala A, Bonkovsky HL, Bishop CE. miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS One. 2018;13:e0200847. doi: 10.1371/journal.pone.0200847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0200847</ArticleId>
            <ArticleId IdType="pmc">PMC6053181</ArticleId>
            <ArticleId IdType="pubmed">30024933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soares e Silva AK, de Oliveira Cipriano Torres D, dos Santos Gomes FO, dos Santos Silva B, Lima Ribeiro E, Costa Oliveira A, dos Santos LA, de Lima Mdo C, Pitta Ida R, Peixoto CA. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD) PLoS One. 2015;10:e0123787. doi: 10.1371/journal.pone.0123787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0123787</ArticleId>
            <ArticleId IdType="pmc">PMC4397012</ArticleId>
            <ArticleId IdType="pubmed">25875942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc. 2015;90:1233–1246. doi: 10.1016/j.mayocp.2015.06.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2015.06.013</ArticleId>
            <ArticleId IdType="pmc">PMC4567478</ArticleId>
            <ArticleId IdType="pubmed">26219858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L, Wang Y, Song Y, Cheng XR, Xia S, Rahman MR, Shi Y, Le G. Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice. Biochem Biophys Res Commun. 2015;458:86–91. doi: 10.1016/j.bbrc.2015.01.072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2015.01.072</ArticleId>
            <ArticleId IdType="pubmed">25640840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21:3777–3785. doi: 10.3748/wjg.v21.i13.3777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v21.i13.3777</ArticleId>
            <ArticleId IdType="pmc">PMC4385525</ArticleId>
            <ArticleId IdType="pubmed">25852263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang LF, Wang XN, Huang CC, Hu L, Xiao YF, Guan XH, Qian YS, Deng KY, Xin HB. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKalpha/SREBP1 signaling pathway. Lipids Health Dis. 2017;16:82. doi: 10.1186/s12944-017-0464-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12944-017-0464-z</ArticleId>
            <ArticleId IdType="pmc">PMC5408374</ArticleId>
            <ArticleId IdType="pubmed">28449683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu GY, Rui C, Chen JQ, Sho E, Zhan SS, Yuan XW, Ding YT. MicroRNA-122 inhibits lipid droplet formation and hepatic triglyceride accumulation via Yin Yang 1. Cell Physiol Biochem. 2017;44:1651–1664. doi: 10.1159/000485765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000485765</ArticleId>
            <ArticleId IdType="pubmed">29216638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada H, Ohashi K, Suzuki K, Munetsuna E, Ando Y, Yamazaki M, Ishikawa H, Ichino N, Teradaira R, Hashimoto S. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta. 2015;446:267–271. doi: 10.1016/j.cca.2015.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cca.2015.05.002</ArticleId>
            <ArticleId IdType="pubmed">25958847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye D, Zhang T, Lou G, Xu W, Dong F, Chen G, Liu Y. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life Sci. 2018;208:201–207. doi: 10.1016/j.lfs.2018.07.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2018.07.029</ArticleId>
            <ArticleId IdType="pubmed">30030064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin S, Fan Y, Zhang H, Zhao Z, Hao Y, Li J, Sun C, Yang J, Yang Z, Yang X, Lu J, Xi JJ. Differential TGFbeta pathway targeting by miR-122 in humans and mice affects liver cancer metastasis. Nat Commun. 2016;7:11012. doi: 10.1038/ncomms11012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms11012</ArticleId>
            <ArticleId IdType="pmc">PMC4802055</ArticleId>
            <ArticleId IdType="pubmed">26987776</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
